Charles River Q3 2026 Earnings Call Transcript
Charles River Laboratories International, Inc. reported solid Q3 2026 financial performance, with revenue and non-GAAP EPS exceeding prior guidance, driven by strong growth in the DSA and manufacturing segments. The company raised its full-year 2026 guidance, expecting continued mid-single-digit growth and significant operating margin expansion. Management expressed optimism about improving biopharmaceutical demand and the long-term tailwind of AI in drug development.
Put this headline into context
Use TradingAgents AI to connect the story to the company's filings, fundamentals, market structure, competing bull and bear arguments, and risk review.
Headlines and excerpts belong to the original publisher. Ticker associations are informational and may be incomplete. Market news is not personalized financial advice.